Literature DB >> 2222186

Priming effect of recombinant vaccinia virus coding for the middle hepatitis B surface antigen.

E Hamsíková1, H Závadová, L Kutinová, V Ludvíková, V Krchnák, S Némecková, V Vonka.   

Abstract

Recombinant vaccinia virus expressing the middle hepatitis B virus surface antigen was incapable of inducing marked antibody response against the S and pre-S2 antigenic specifities in mice. However, mice immunized with this virus produced antibodies to both these antigens after the following administration of subtreshold doses of plasmatic hepatitis B surface antigen.

Entities:  

Mesh：

Substances：

Year:  1990        PMID： 2222186     DOI： 10.1007/bf01316681

Source DB:  PubMed          Journal:  Arch Virol        ISSN： 0304-8608            Impact factor:   2.574


  13 in total

1.  The purification fo four strains of poxvirus.

Authors:  W K JOKLIK
Journal:  Virology       Date:  1962-09       Impact factor: 3.616

Review 2.  Recognition of influenza virus proteins by cytotoxic T lymphocytes.

Authors:  A R Townsend
Journal:  Immunol Res       Date:  1987       Impact factor: 2.829

3.  Study of plaque titration of vaccinia virus in chick embryo cell cultures. I. Assays under an agar overlay.

Authors:  D Slonim; M Hulenová
Journal:  Acta Virol       Date:  1969-05       Impact factor: 1.162

4.  Enhanced immunogenicity of the pre-S region of hepatitis B surface antigen.

Authors:  D R Milich; G B Thornton; A R Neurath; S B Kent; M L Michel; P Tiollais; F V Chisari
Journal:  Science       Date:  1985-06-07       Impact factor: 47.728

5.  Normal rat cell lines deficient in nuclear thymidine kinase.

Authors:  W C Topp
Journal:  Virology       Date:  1981-08       Impact factor: 3.616

6.  General method for production and selection of infectious vaccinia virus recombinants expressing foreign genes.

Authors:  M Mackett; G L Smith; B Moss
Journal:  J Virol       Date:  1984-03       Impact factor: 5.103

7.  Transcription of the hepatitis B surface antigen gene in mouse cells transformed with cloned viral DNA.

Authors:  C Pourcel; A Louise; M Gervais; N Chenciner; M F Dubois; P Tiollais
Journal:  J Virol       Date:  1982-04       Impact factor: 5.103

8.  A recombinant vaccinia virus expressing hepatitis B virus middle surface protein. Restricted expression of HBV antigens in human diploid cells.

Authors:  L Kutinová; S Nĕmecková; E Hamsíková; M Press; H Závadová; I Hirsch; V Nĕmecek; V Krchnák; J Smrt; D Slonim
Journal:  Arch Virol       Date:  1990       Impact factor: 2.574

9.  Selective synthesis and secretion of particles composed of the hepatitis B virus middle surface protein directed by a recombinant vaccinia virus: induction of antibodies to pre-S and S epitopes.

Authors:  K C Cheng; B Moss
Journal:  J Virol       Date:  1987-04       Impact factor: 5.103

10.  Anti-pre-S2 antibodies in natural hepatitis B virus infection and after immunization.

Authors:  P Coursaget; P Adamowicz; C Bourdil; B Yvonnet; Y Buisson; J L Barrès; P Saliou; J P Chiron; I D Mar
Journal:  Vaccine       Date:  1988-08       Impact factor: 3.641
View more
  3 in total

1.  Attenuation of vaccinia virus by the expression of human Flt3 ligand.

Authors:  Kamila Zurkova; Petr Hainz; Jitka Krystofova; Luda Kutinova; Miloslav Sanda; Sarka Nemeckova
Journal:  Virol J       Date:  2010-05-26       Impact factor: 4.099

2.  Hepatitis B virus proteins expressed by recombinant vaccinia viruses: influence of preS2 sequence on expression surface and nucleocapsid proteins in human diploid cells.

Authors:  L Kutinová; S Nĕmecková; E Hamsíková; H Závadová; V Ludvíková; J Broucek; D Kunke; J König; L G Zakharova; G V Pashvykina
Journal:  Arch Virol       Date:  1994       Impact factor: 2.574

3.  Synthesis and immunogenicity of hepatitis B virus envelope antigen expressed by recombinant vaccinia virus. Finding of retention signal in the C-terminal portion of the preS1 domain of subtype adyw.

Authors:  S Nĕmecková; L Kutinová; E Hamsíková; D Kunke; M Press; H Závadová; J Smrt; V Vonka
Journal:  Arch Virol       Date:  1991       Impact factor: 2.574
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.